Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002
Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010
The biology of lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=61 Year: 2001
Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005
LSC 2012 abstract – Effects of the Hedgehog (Hh) pathway inhibitor GDC-0449 on lung cancer cells and cisplatin resistant lung cancer cells are mediated by lung cancer stem cells (SPs) Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
New chemotherapeutic agents Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=259 Year: 2001
The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005
The loss of pulmonary barrier function as a result of application of anticancer agents paclitaxel, 2-methoxyestradiol, and their combination Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010
A possible role of intracellular calcium in the development of anti-cancer therapy -resistance in lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 853s Year: 2006
New concepts in pulmonary oncology Source: ISSN=ISSN 1025-448x, ISBN=ISBN 978-1-904097-51-8, page=63 Year: 2007
Formation of tumor fragment spheroids (TFS) from lung cancer, in vitro model as like in vivo Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD Year: 2019
Extracts of lung cancer cells reveal antitumour antibodies in sera of patients with lung cancer Source: Eur Respir J 2003; 21: 342-346 Year: 2003
Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer Source: Eur Respir J 2002; 19: 557-570 Year: 2002
D104N poluymorphism in endostatin, an angiogenesis inhibitor, in lung cancer susceptibility Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010
The activity and toxicity of gemcitabine and paclitaxel in previously treated patients with small cell lung cancer (SCLC); preliminary results Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004
Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017